Cargando…
Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution
None of the clinical trials on migraine conducted thus far have focused on the possibility to modulate the phenomenon of aura. Furthermore, whether proper management of aura results in a better control of the headache phase has been poorly investigated. In the setting of a single-center, pilot, clin...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803726/ https://www.ncbi.nlm.nih.gov/pubmed/31687058 http://dx.doi.org/10.1155/2019/6320163 |
_version_ | 1783461007911288832 |
---|---|
author | Volta, Giorgio Dalla Zavarise, Paola Perego, Laura Savi, Lidia Pezzini, Alessandro |
author_facet | Volta, Giorgio Dalla Zavarise, Paola Perego, Laura Savi, Lidia Pezzini, Alessandro |
author_sort | Volta, Giorgio Dalla |
collection | PubMed |
description | None of the clinical trials on migraine conducted thus far have focused on the possibility to modulate the phenomenon of aura. Furthermore, whether proper management of aura results in a better control of the headache phase has been poorly investigated. In the setting of a single-center, pilot, clinical trial, we aimed at comparing the effects of Aurastop (a combination of tanacetum parthenium (150 mg extracted at 0.8% = 1.2 mg di of active parthenolide), griffonia simplicifoila (20 mg of 5-hydroxy tryptophan), and magnesium (185 mg of magnesium pidolatum)) with those of magnesium alone (2.25 grams/tablet, corresponding to 184 mg of Mg++) in the treatment of acute attacks of migraine with aura. Between June 2017 and June 2018, 50 consecutive patients (27/23 male/female; mean age, 31 [18–57] years) with at least 3 episodes of aura per year were included (t(0)). Participants were instructed to keep track of the following 4 episodes of migraine with aura (t(1)) and invited to assume (1) a tablet of Aurastop at the beginning of the following 2 episodes of aura and (2) a magnesium tablet alone at the occurrence of the third and fourth aura attacks. Forty-eight patients (96.0%) had >50% reduction in aura duration when treated with Aurastop vs. 7 patients (14.0%) when treated with magnesium alone (p < 0.001); 48 patients (96.0%) had >50% reduction of aura-related disability when receiving Aurastop vs. 5 patients (10.0%) when treated with magnesium alone (p < 0.001); however, patients receiving Aurastop did not need to take pain killers in 35% of aura attacks vs. 3% when assuming magnesium (p < 0.001). These results support the hypothesis that Aurastop might be effective in interfering with the phenomenon of aura and provide evidence that the clinical benefit attributable to this combination of molecules might be greater than that obtained with single compounds of proven effect on the biology of migraine. |
format | Online Article Text |
id | pubmed-6803726 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-68037262019-11-04 Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution Volta, Giorgio Dalla Zavarise, Paola Perego, Laura Savi, Lidia Pezzini, Alessandro Pain Res Manag Research Article None of the clinical trials on migraine conducted thus far have focused on the possibility to modulate the phenomenon of aura. Furthermore, whether proper management of aura results in a better control of the headache phase has been poorly investigated. In the setting of a single-center, pilot, clinical trial, we aimed at comparing the effects of Aurastop (a combination of tanacetum parthenium (150 mg extracted at 0.8% = 1.2 mg di of active parthenolide), griffonia simplicifoila (20 mg of 5-hydroxy tryptophan), and magnesium (185 mg of magnesium pidolatum)) with those of magnesium alone (2.25 grams/tablet, corresponding to 184 mg of Mg++) in the treatment of acute attacks of migraine with aura. Between June 2017 and June 2018, 50 consecutive patients (27/23 male/female; mean age, 31 [18–57] years) with at least 3 episodes of aura per year were included (t(0)). Participants were instructed to keep track of the following 4 episodes of migraine with aura (t(1)) and invited to assume (1) a tablet of Aurastop at the beginning of the following 2 episodes of aura and (2) a magnesium tablet alone at the occurrence of the third and fourth aura attacks. Forty-eight patients (96.0%) had >50% reduction in aura duration when treated with Aurastop vs. 7 patients (14.0%) when treated with magnesium alone (p < 0.001); 48 patients (96.0%) had >50% reduction of aura-related disability when receiving Aurastop vs. 5 patients (10.0%) when treated with magnesium alone (p < 0.001); however, patients receiving Aurastop did not need to take pain killers in 35% of aura attacks vs. 3% when assuming magnesium (p < 0.001). These results support the hypothesis that Aurastop might be effective in interfering with the phenomenon of aura and provide evidence that the clinical benefit attributable to this combination of molecules might be greater than that obtained with single compounds of proven effect on the biology of migraine. Hindawi 2019-10-09 /pmc/articles/PMC6803726/ /pubmed/31687058 http://dx.doi.org/10.1155/2019/6320163 Text en Copyright © 2019 Giorgio Dalla Volta et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Volta, Giorgio Dalla Zavarise, Paola Perego, Laura Savi, Lidia Pezzini, Alessandro Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution |
title | Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution |
title_full | Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution |
title_fullStr | Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution |
title_full_unstemmed | Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution |
title_short | Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution |
title_sort | comparison of the effect of tanacethum parthenium, 5-hydroxy tryptophan, and magnesium (aurastop) versus magnesium alone on aura phenomenon and its evolution |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803726/ https://www.ncbi.nlm.nih.gov/pubmed/31687058 http://dx.doi.org/10.1155/2019/6320163 |
work_keys_str_mv | AT voltagiorgiodalla comparisonoftheeffectoftanacethumparthenium5hydroxytryptophanandmagnesiumaurastopversusmagnesiumaloneonauraphenomenonanditsevolution AT zavarisepaola comparisonoftheeffectoftanacethumparthenium5hydroxytryptophanandmagnesiumaurastopversusmagnesiumaloneonauraphenomenonanditsevolution AT peregolaura comparisonoftheeffectoftanacethumparthenium5hydroxytryptophanandmagnesiumaurastopversusmagnesiumaloneonauraphenomenonanditsevolution AT savilidia comparisonoftheeffectoftanacethumparthenium5hydroxytryptophanandmagnesiumaurastopversusmagnesiumaloneonauraphenomenonanditsevolution AT pezzinialessandro comparisonoftheeffectoftanacethumparthenium5hydroxytryptophanandmagnesiumaurastopversusmagnesiumaloneonauraphenomenonanditsevolution |